Fallopian Tube Carcinoma
📧 Sign up to get email alerts when something new happens for Fallopian Tube Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [Phase 1]
This is a Phase 1 clinical trial evaluating genetically modified T cells in combination with decitabine for recurrent or refractory ovarian,…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer [Phase 2]
A Phase 2 clinical trial evaluating pembrolizumab in combination with bevacizumab, with or without the anti-CD40 agonist CDX-1140, for recur…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy [Phase 2]
Phase 2 trial evaluating a standardized AHCC extract in ovarian cancer patients on adjuvant chemotherapy; the study is currently active but …
-
CLINICAL_TRIALS trial_result · 2025-07-23Clinical Trial Update: NM32-2668 in Adult Patients With Selected Advanced Solid Tumors [Phase 1]
A Phase 1 trial of NM32-2668 in adults with selected advanced solid tumors has been terminated. The study enrolled multiple tumor types incl…
-
CLINICAL_TRIALS other · 2025-05-15Clinical Trial Update: NGS-based Germline and Somatic Genetic Test in Ovarian Carcinoma [Phase 4]
Clinical trial status update for a Phase 4 study evaluating an NGS-based germline and somatic genetic test in ovarian carcinoma and related …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-02-26Clinical Trial Update: SCT-001 CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer [Phase 1]
A Phase 1 clinical trial of SCT-001 CAR T Cells Therapy for relapsed and refractory ovarian cancer and related peritoneal cancers is not yet…
-
CLINICAL_TRIALS trial_result · 2024-10-24Clinical Trial Update: Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 1, Phase 2]
Clinical trial update reporting results from a Phase 1/2 study of ruxolitinib phosphate in combination with paclitaxel and carboplatin for S…
-
CLINICAL_TRIALS withdrawal · 2024-08-21Clinical Trial Update: Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199
The NCT01445275 trial on the cost of cancer risk management in women at elevated genetic risk for ovarian cancer has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2024-07-12Clinical Trial Update: Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives
A completed clinical trial update examining factors influencing cascade genetic testing among women with hereditary gynecologic cancers and …
-
CLINICAL_TRIALS trial_result · 2023-11-08Clinical Trial Update: Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) [Phase 3]
Phase 3 evaluation of adding AL3818 to standard platinum-based chemotherapy for recurrent or metastatic gynecologic carcinomas is in progres…
-
CLINICAL_TRIALS trial_result · 2023-02-24Clinical Trial Update: DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission [Phase 1, Phase 2]
Phase 1/2 trial evaluating CDX-1401, Poly ICLC, and INCB024360 in remission for ovarian, fallopian tube, or primary peritoneal cancer comple…
-
CLINICAL_TRIALS trial_result · 2023-01-19Clinical Trial Update: Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 2]
Phase 2 clinical trial evaluating irinotecan liposome with bevacizumab for platinum-resistant or recurrent ovarian, fallopian tube, or prima…
-
CLINICAL_TRIALS trial_result · 2022-12-30Clinical Trial Update: Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer [Phase 2]
Phase 2 trial update on neoadjuvant chemotherapy for epithelial ovarian cancer with related fallopian tube and peritoneal carcinomas; curren…
-
CLINICAL_TRIALS trial_result · 2022-06-10Clinical Trial Update: First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer [Phase 2]
A Phase 2 trial evaluating first-line bevacizumab, carboplatin, and paclitaxel in stage III-IV ovarian, primary peritoneal, and fallopian tu…
-
CLINICAL_TRIALS trial_result · 2021-10-20Clinical Trial Update: Pemetrexed and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [Phase 2]
Phase 2 clinical trial evaluating pemetrexed and carboplatin for recurrent ovarian, primary peritoneal, or fallopian tube cancer has complet…
-
CLINICAL_TRIALS trial_result · 2020-12-14Clinical Trial Update: Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma [Phase 2]
A Phase 2 trial evaluating chemotherapy in ovarian, fallopian tube, and peritoneal carcinoma has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-11-06Clinical Trial Update: Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 2]
Phase 2 clinical trial evaluating pembrolizumab, bevacizumab, and cyclophosphamide in recurrent ovarian, fallopian tube, or primary peritone…
-
CLINICAL_TRIALS trial_result · 2020-03-31Clinical Trial Update: Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer [Phase 2]
A Phase 2 clinical trial evaluating the combination of everolimus and letrozole in patients with recurrent hormone receptor-positive ovarian…
-
CLINICAL_TRIALS trial_result · 2020-03-10Clinical Trial Update: Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer [Phase 2]
Phase 2 trial evaluating cabozantinib versus paclitaxel for persistent or recurrent epithelial ovarian, fallopian tube, or primary peritonea…
-
CLINICAL_TRIALS trial_result · 2020-03-10Clinical Trial Update: Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 2]
Phase 2 clinical trial update for cabozantinib-s-malate in recurrent or progressive ovarian, fallopian tube, or primary peritoneal cancer.
-
CLINICAL_TRIALS trial_result · 2019-10-30Clinical Trial Update: Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer [Phase 2]
Phase 2 trial evaluating paclitaxel with or without viral therapy in recurrent or persistent ovarian, fallopian tube, or primary peritoneal …
-
CLINICAL_TRIALS trial_result · 2019-09-17Clinical Trial Update: Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer [Phase 2]
Phase 2 trial evaluating elesclomol sodium with paclitaxel in patients with recurrent or persistent ovarian epithelial cancer, fallopian tub…
-
CLINICAL_TRIALS trial_result · 2019-05-17Clinical Trial Update: Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer [Phase 2]
Phase 2 trial evaluating dasatinib in recurrent or persistent ovarian, fallopian tube, endometrial, or peritoneal cancers; study terminated …
-
CLINICAL_TRIALS trial_result · 2017-12-08Clinical Trial Update: Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer [Phase 2]
Phase 2 trial update for dalantercept in recurrent ovarian, fallopian tube, or primary peritoneal cancer; study completed with results poste…
-
CLINICAL_TRIALS trial_result · 2017-11-30Clinical Trial Update: EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer [Phase 2]
Phase 2 clinical trial update for EGEN-001 in persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritonea…